2021 survey highlights challenges and opportunities for investigators, coordinators, and patients.
It is crucial throughout the clinical trials space to understand the challenges and triumphs of DEI.
Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Understanding the role of social determinants on clinical trial participation and trust.
Recent study results highlight need for new metrics in ECOG scoring to mitigate variability.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Sites not expected to fade away even as DCTs continue to grow past COVID-19.
Presenting how data transformation is measured as part of the SAFE Data Standard, which data variables influence the rating and, how the appropriate level of data transformation is calculated.
The adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Education and equitable access are key to unlocking its full potential in the present and future.
The pursuit of balance between data utility, privacy protection, and equitable representation.
Study evaluates the use of AI-supported medical coding module.
A discussion of how the coronavirus pandemic will have a multitude of impacts on the conduct of trials, as well as on the industry itself.
Beyond technology, awareness, and access—cultural competence is key.
Using the promising-zone approach can salvage an underpowered trial.
How advanced ePRO tools and approaches offer a path forward.
Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.
What the next generation medication management in clinical trials should entail and insights on smart technologies and synergistic partnerships—backed by real-life implementation use cases.
Five strategies to reduce risk and achieve deadlines.
While Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
Industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.
The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Today’s clinical studies are increasingly complex and require patient-centric trial designs, like decentralized trials, more than ever before. As trials incorporate more decentralized components there is an ever-present need for multiple system integrations to support the various trial functions, with the goal being that all trial data flows seamlessly between systems and is stored in one repository for efficient oversight and analysis. These numerous integrated systems require closely managed integration, synchronization, and supportive partnerships to minimize error and maximize efficiency. In this case study, partners endpoint and THREAD dig-in to explore how IRT can be integrated with decentralized clinical trial (DCT) technology, working through tightly integrated workflows, to provide a streamlined process, a better user experience for Sites and Participants, higher quality data and real-time access to information.
Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge.
Using surveys to collect various viewpoints on eConsent from ethics, sponsors, and vendors.